Prescription medication · SGLT2 / DPP-4 Combination

empagliflozin/linagliptin

Also sold as Glyxambi. Glyxambi is used to improve blood sugar control in adults with type 2 diabetes.

Data updated 2026-05-15

872
FDA reports
11
InteractionsSeveral interactions
$19.57
Brand price (NADAC)

What the data shows

empagliflozin/linagliptin (Glyxambi) is a prescription SGLT2 / DPP-4 Combination, with 872 FDA adverse-event reports on file, with 11 documented drug interactions.

Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.

empagliflozin/linagliptin (Glyxambi) is a prescription SGLT2 / DPP-4 Combination. Glyxambi is used to improve blood sugar control in adults with type 2 diabetes.

Glyxambi is a drug that combines three medicines to help lower blood sugar in adults with type 2 diabetes. It can also lower the risk of death from heart problems in those with both type 2 diabetes and heart disease.

Verify with FDA → · CMS NADAC pricing →

Drug Pricing (NADAC)

Brand Price

$19.57/unit

Generic Available

No

Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →

Compare with Another Drug →

What it does

Glyxambi is used to improve blood sugar control in adults with type 2 diabetes.

Common side effects

Upper respiratory infection (like a cold), Urinary tract infection, Runny or stuffy nose

Key warnings

Glyxambi contains metformin, which can cause a serious side effect called lactic acidosis.

The sections below are summarized in plain English from empagliflozin/linagliptin's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.

How It Works

Glyxambi works in three ways to lower blood sugar. Empagliflozin helps your kidneys remove sugar from your blood through urine. Linagliptin helps your body release more insulin after meals. Metformin helps to decrease the amount of sugar your liver makes and helps your body use insulin better.

Side Effects (from patient reports)

Based on 872 FDA adverse event reports.

Most-reported reactions

Adverse reactions in FAERS for empagliflozin/linagliptin, by number of reports

reports

What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.

Source FDA Adverse Event Reporting System (FAERS)

Serious Warnings

Glyxambi contains metformin, which can cause a serious side effect called lactic acidosis. Lactic acidosis is a buildup of lactic acid in the blood. It can be life-threatening. Get medical help right away if you have symptoms like feeling very weak, tired, or uncomfortable; unusual muscle pain; trouble breathing; stomach pain with nausea and vomiting; feeling cold, especially in your arms and legs; feeling dizzy or lightheaded; or a sudden change in your heartbeat.

Known Drug Interactions

moderate metformin

Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] . Alcohol Clinical Impact Alcohol is known to potentiate the effect of metformin on lactate metabolism. ( 7 ) Drugs that...

Mechanism: Taking these medications together can cause metformin to build up in your blood because the kidneys cannot remove it as quickly. This increase can lead to a dangerous condition where too much acid builds up in your blood.

moderate dolutegravir

Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] .

Mechanism: Dolutegravir blocks the kidneys from filtering metformin out of your blood, which makes metformin levels rise. Higher levels of metformin increase the risk of a serious health problem called lactic acidosis.

moderate ranolazine

Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] .

Mechanism: Ranolazine prevents the kidneys from properly removing metformin from your system, leading to higher amounts of the drug in your body. This can increase the chance of developing a dangerous buildup of acid in your blood.

moderate cimetidine

Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] .

Mechanism: Cimetidine interferes with how the kidneys get rid of metformin, which can cause the drug to build up in your body. High levels of metformin increase the risk of a life-threatening condition called lactic acidosis.

minor empagliflozin

Diuretics Clinical Impact Coadministration of empagliflozin with diuretics resulted in increased urine volume and frequency of voids, which might enhance the potential for volume depletion.

Mechanism: Both of these medicines increase how much you urinate. This can cause your body to lose too much water and become dehydrated.

Check all your medications →

This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.

Common Questions

What should I do if I experience severe joint pain while taking Glyxambi?
Tell your doctor right away. Severe joint pain has been reported with linagliptin, one of the medicines in Glyxambi. Your doctor may have you stop taking Glyxambi.
Can Glyxambi cause low blood sugar?
Yes, especially if you are also taking insulin or a sulfonylurea. Your doctor may need to lower the dose of your other diabetes medicines.
Will Glyxambi cause me to lose weight?
Weight loss is not a common side effect, but it can happen in some people.
Can Glyxambi affect my kidneys?
Yes, Glyxambi can affect your kidneys. Your doctor will check your kidney function before you start taking Glyxambi and regularly while you are taking it.
Can Glyxambi cause a bladder infection?
Yes, Glyxambi can increase your risk of urinary tract infections.
Is it safe to drink alcohol while taking Glyxambi?
Avoid drinking too much alcohol while taking Glyxambi, as it can increase your risk of lactic acidosis.
Does Glyxambi interact with other medications?
Yes, Glyxambi can interact with other medications. Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Can Glyxambi cause heart failure?
Heart failure has been seen with similar drugs. Tell your doctor if you have heart problems or risk factors for heart failure.
What are the symptoms of lactic acidosis?
Symptoms include feeling very weak, tired, or uncomfortable; unusual muscle pain; trouble breathing; stomach pain with nausea and vomiting; feeling cold, especially in your arms and legs; feeling dizzy or lightheaded; or a sudden change in your heartbeat.
Should I stop taking Glyxambi before a surgery or procedure?
Yes, you may need to stop Glyxambi before surgery or certain procedures. Talk to your doctor about this.
What are the common side effects of empagliflozin/linagliptin?
The registry lists Upper respiratory infection (like a cold), Urinary tract infection, Runny or stuffy nose, Diarrhea, Constipation among the most-reported FAERS reaction terms for empagliflozin/linagliptin. The compiled record contains 872 FDA adverse-event reports. These counts are not an individual symptom assessment.
Does empagliflozin/linagliptin interact with other medications?
The registry has 11 documented interaction rows for empagliflozin/linagliptin. Notable source-record pairings include metformin, dolutegravir, ranolazine. These rows are not a complete medication review.
What drug class is empagliflozin/linagliptin?
empagliflozin/linagliptin belongs to the SGLT2 / DPP-4 Combination drug class. It requires a prescription (Rx). Glyxambi is used to improve blood sugar control in adults with type 2 diabetes.
What pregnancy or breastfeeding source fields are listed for empagliflozin/linagliptin?
The FDA label for empagliflozin/linagliptin contains product-specific pregnancy or breastfeeding language. PlainMeds does not apply that source text to an individual.

Related Medications in SGLT2 / DPP-4 Combination

Other drugs grouped near empagliflozin/linagliptin - same-class peers and common alternatives.

acarbose

Precose

Acarbose is a medicine that helps lower blood sugar levels in people with type 2 diabetes.

Compare with empagliflozin/linagliptin →

alogliptin

Nesina

Compare with empagliflozin/linagliptin →

bromocriptine

Cycloset

Bromocriptine (Cycloset) is a medicine that acts like dopamine in your body.

Compare with empagliflozin/linagliptin →

canagliflozin

Invokana

Invokana is a medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes.

Compare with empagliflozin/linagliptin →

colesevelam

Welchol

Colesevelam is a medicine that helps lower bad cholesterol (LDL-C) and control blood sugar in adults.

Compare with empagliflozin/linagliptin →

Compare empagliflozin/linagliptin vs acarbose side-by-side →

Medication Guides

Understanding Drug Interactions

How CYP450 enzymes, inhibitors, and inducers affect your medications

Generic vs Brand Name Drugs

FDA requirements, cost savings, and when the difference matters

Narrow Therapeutic Index Drugs

FDA bioequivalence and label-record context for narrow therapeutic index medicines

Common Drug Interactions

Dangerous medication combinations and how to protect yourself

Save on empagliflozin/linagliptin

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Check Prices on GoodRx →

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for empagliflozin/linagliptin

The FDA label for empagliflozin/linagliptin (sold under brand names such as Glyxambi) classifies it as a prescription-only medication in the SGLT2 / DPP-4 Combination class. Glyxambi is used to improve blood sugar control in adults with type 2 diabetes. Official labeling lists 7 commonly reported side effects, including Upper respiratory infection (like a cold), Urinary tract infection, Runny or stuffy nose.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 872 voluntary reports. The database also lists 11 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS.

Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.

Last updated: January 30, 2026

PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.

Read our methodology - how this data is sourced, computed, and verified.

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.

All federal data sources used on this page